Combined Angiography Market By Type (Discovery IGS System, MIYABI Angio-CT, Trinias Series MiX Package, INFX-8000C + CT (Aquilion), Allura Clarity & Others), By Disease (Cardiac disease, Brain disease, Renal Disease, & Others), By End Users (Hospitals, Diagnostic Centers, Research Centers, & Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027

Report Code: HCR 0604 Report Format: PDF + Excel

Combined Angiography Market Overview

Combined Angiography Market Size is estimated to reach $9.8 billion by 2027. Furthermore, it is poised to grow at a CAGR of 5.8% over the forecast period of 2022-2027. Angiography is a type of X-ray imaging in which contrasting chemicals are injected into the bloodstream to help visualize and comprehend blood vessel disorders such as aneurysms and atherosclerosis. It's frequently used to diagnose heart problems like coronary artery disease. New angiography techniques include computed tomography (CT), angiography, and magnetic resonance imaging (MRI) angiography, which diagnose anomalies in blood arteries. Past treatments and diagnosis methods are more complicated; hence device is used to treat abnormalities that are installed in different chambers. So patients have to move from one room to another, which is hectic and time-consuming. Now this problem is resolved using the new technique of combined angiography. These systems contain a unique 3D application that links angiography systems to CT images taken during the interventional procedure. As a result, the devices provide superior image quality and make surgery easier for doctors. According to CDC 659000 people in the United States died from heart disease each year and 805000 people have heart attacks every year. People are subjected to heart disease hectic lifestyle conditions such as unhealthy food consumption, addiction to alcohol and smoking, also lifestyle-related diseases like diabetes, and blood pressure. As increasing lifestyle diseases demand the need for combined angiography which helps to boost the Combined Angiography Market over the forecast period 2022 – 2027.

Report Coverage

The report: “Combined Angiography Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Combined Angiography Market.

By Type: Discovery IGS System, MIYABI Angio-CT, Trinias Series MiX Package, INFX-8000C + CT (Aquilion), Allura Clarity and Others.
By Disease: Cardiac disease, Brain disease, Renal Disease, and Others.
By End Users: Hospitals, Diagnostic Centers, Research Centers, and Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021, owing to advanced health infrastructure in countries like the United States and Canada.
  • The Combined Angiography Market is predicted to increase owing to the increasing number of cardiac cases hence hectic lifestyle, consumption of unhealthy food, and addiction
  • However, the high cost of equipment and setup along with strict government restrictions in some countries may limit market growth over the forecast period 2022-2027.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Combined Angiography Market.

Combined Angiography Market: Market Share (%) by region, 2021

Combined Angiography Market

For More Details on This Report - Request for Sample

Combined Angiography Market Segmentation Analysis- By Product Type

Combined Angiography Market based on type can be further segmented into Discovery IGS System, MIYABI Angio-CT, Trinias Series MiX Package, INFX-8000C + CT (Aquilion), Allura Clarity, and Others. Discovery IGS System segment held a dominant market share in the year 2021, owing to the technology of IGS7 which is known for the very high quality of images and gives complete workplace freedom to the hybrid operating room. It gives high-end fluoroscopy image guidance used in advanced applications; 3D image fusion with laser-guided precision.

However, the Trinias Series MiX Package segment is estimated to grow with the fastest CAGR rate of 6.5% over the forecast period 2022-2027. Owing to the all-in-one imaging system. It combines CT, angiography, and ultrasound features in one device which helps to provide fast access to information about the patient health conditions. This technology gives clear pictures and quick treatments based on pictures. This technique cuts costs by reducing multiple types of equipment needed for diagnosis. Which will help to boost the market for combined angiography over the forecast period 2022-2027.

Combined Angiography Market Segmentation Analysis- By End Users

Combined Angiography Market based on end users can be further segmented into Hospitals, Diagnostic Centres, Research Centres, and Others. The Hospital segment held a dominant market share in the year 2021. This is owing to the use of detecting technology in radiology of hospitals to detect aneurysms, recognize blood vessel damage caused by trauma or injury, diagnose cardiovascular disorders such as artery narrowing, etc. In 2021, the number of specialty hospitals in China are 5127 according to Cambridge. Such an increasing number of hospitals and radiology departments to diagnose cardiac diseases support the growth of the Combined Angiography Market.

However, Diagnostic Centres are estimated to grow with the fastest CAGR rate of 7.1% over the forecast period 2022-2027. Owing to the use of combined angiography mostly to diagnose peripheral vascular diseases. Cardiac diseases are increasing rapidly as increasing urbanization and stress life. According to research, 284 million people suffer from anxiety disorders. According to a survey by American Psychological Association in 2020, 65% of Americans suffered from stress due to uncertainty in America. Such increasing health issues worldwide help to boost the diagnostic center's segment.

Combined Angiography Market Segmentation Analysis- By Geography

The Combined Angiography Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 33% in the year 2021. Owing to the increasing number of the elderly population and low ability to create immunity against diseases due to stressful lifestyles. According to The Administration of Community Living – in 2019 in the U.S the population above 65+ was 54.1 million, from which 30 million are women and 24.1million men. And also, loneliness in the elderly population is one of the reasons behind these diseases. According to the Pew research center in 2020, near about 27% of elder people with age 60 and above are living alone. With the increase in the aged population in the U.S., North America leads the dominant segment of the Combined Angiography Market.

Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. According to better healthcare infrastructure and the fastest increasing old age population in the Asia-Pacific region. According to the Economic and Social Commission for Asia and the Pacific, by 2050 nearly 8 in 10 of the world's older population will live in the less developed regions. Nearly about 1.3 billion people 60 years and above will live in Asia-Pacific. According to APAC health CIO report- increasing investment in cybersecurity, automation and digital literacy in the healthcare sector is fuelling the healthcare sector in the APAC region, which boosts the Combined Angiography Market in the Asia-Pacific region.

Combined Angiography Market Drivers

The Market Is Being Driven by increasing the Number of Aged Population Around the World

The world population is rapidly aging as a result of different government programs aimed at accelerating the longevity revolution. The majority of wealthy countries are seeing an increase in the number of elderly people. According to UN estimates, there were 703 million people aged 65 and more in 2019, with that number anticipated to rise to 1.5 billion by 2050. The incidence of chronic diseases is rising over the world, particularly in terms of hypertension, diabetes, and cardiac diseases. According to WHO, Cardiovascular disease (CVD) is the leading cause of death worldwide, approximately 17.9 million people died due to CVD in 2019, and 85% of deaths is due to heart attack and stroke. Such an increasing population of old age people and an increasing percentage of CVD and related diseases drive the Combined Angiography Market.

Growing Technological Enhancements Drives the Market Growth

As governments and healthcare firms throughout the world are focused on better healthcare infrastructure as well as research and development for better diagnosis and treatment as essential diseases such as CVD, cancer, and neurological diseases become more prevalent. According to a Niti Ayog estimate, India would get up to $50 billion in foreign direct investment (FDI) in 2019-2020. India also allowed 100% FDI in the healthcare sector which helps to strengthen the healthcare industry in India. Innovation in the healthcare industry raised $44 billion globally in 2021 as per start-up health research insight. 3D printing is gaining traction in the treatment of cardiovascular disease and has the potential to be utilized in disease prevention. Aortic valve dysfunction can be treated without the use of prosthetic valves with the use of 3D-printed heart valves derived from living tissue. Such innovation and investment in the healthcare sector are driving the Combined Angiography Market.

Combined Angiography Market Challenges

High Cost of Treatment and Certain Health Issues Limit Market Growth

The CVD diagnosis technique uses radiation, which can have a variety of negative effects on the skin and tissue, as well as the potential to induce cancer. The typical cost of an angiography system will be $ 1.5 million, which will raise the whole treatment cost. The hospital's per-bed-per-day costs for admitted patients in the Cardiac Care Unit, adult cardiology ward, and pediatric cardiology ward were assessed to be INR 28,144 (US$ 434), INR 22,210 (US$ 342), and INR 18,774 (US$ 289), respectively, according to a research report published in PLOSONE. Inpatient costs accounted for about 70% of total costs, with equipment costs accounting for more than half of inpatient costs, followed by human resource costs (28 %). The cost of treating any CVD per patient was estimated to be INR 2,47,822 (US$ 3842). Rheumatic Heart Disease had the highest treatment costs of all CVDs, followed by Cardiomyopathy and other CVDs. In the United States, $ 216 billion is spent on health care each year, resulting in a $147 billion loss in productivity. The rising expense of CVD and related diseases, as well as their influence on patients' and countries' economies, limit market expansion.

Combined Angiography Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Combined Angiography Market. The top 10- Combined Angiography Market companies are-

  1. Philips healthcare
  2. GE Healthcare
  3. Toshiba Corporation
  4. Siemens healthcare
  5. Shimadzu Corporation
  6. Omega SA
  7. Estate Spa
  8. Pie Medical imaging
  9. Even Medical Inc.
  10. Nevada technologies Inc.

Recent Developments

  • In March 2022, GE Healthcare and Wipro joint venture launched a manufacturing plant of 100 crores in Bengaluru, under a government production linked initiative scheme. The company is set under the government initiative of ‘Atmanirbhar Bharat’ to boost local manufacturing of medical devices in India. The plant is set up on 35000 sq. ft for the manufacturing of CT machines, Cath-lab equipment, ultrasound scanners, patient monitoring solutions, ECG machines, and Ventilators.
  • In June 2021, Siemens healthcare announced a 10-year strategic partnership with Prisma Health, with the aim to create a better state of health for South Carolina. This joint venture creates opportunities to enhance clinical care, development of latest technology, streaming process, and better disease prevention, early diagnosis, and treatment.
  • In January 2021, Philips healthcare, expand its leadership in patient care management solution for hospitals by the acquisition of Capsule Technology, Inc., which is known for its Medical device information platform and provide medical device integration and data technologies for hospitals' health care organization. The acquisition cost is $635 million.

Relevant Titles

Cardiac Monitoring & Cardiac Rhythm Management Market - Forecast(2022 - 2027)

Report Code: HCR 47458

Cardiac Assist Devices Market - Forecast(2022 - 2027)

Report Code: HCR 0834

CT Scanners Market - Forecast(2022 - 2027)

Report Code: HCR 0169

 For more Lifesciences and Healthcare Market reports, please click here

1. Combined Angiography Market – Overview
    1.1 Definitions and Scope
2. Combined Angiography Market- Executive Summary
3. Combined Angiography Market- Comparative Analysis
    3.1 Company Benchmarking - Key Companies
    3.2 Global Financial Analysis - Key Companies
    3.3 Market Share Analysis - Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Combined Angiography Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Combined Angiography Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Combined Angiography Market- Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Combined Angiography Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Combined Angiography Market – By Type
    8.1 Discovery IGS System
    8.2 MIYABI Angio-CT
    8.3 Trinias Series MiX Package
    8.4 INFX-8000C + CT (Aquilion)
    8.5 Allura Clarity
    8.6 Others
9. Combined Angiography Market – By Disease
    9.1 Cardiac Disease
    9.2 Brain Disease
    9.3 Renal Disease
    9.4 Others
10. Combined Angiography Market – By End Users
    10.1 Hospitals
    10.2 Diagnostic Centres
    10.3 Research Centers
    10.4 Others
11. Combined Angiography Market- By Geography
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 Rest of South America
12. Rest of the World
    12.1 Middle East
    12.2 Africa
13. Combined Angiography Market- Entropy
14. Combined Angiography Market – Industry/Segment Competition Landscape Premium 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Combined Angiography Market – Key Company List by Country Premium Premium
16. Combined Angiography Market- Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.